Belatacept in clinical and experimental transplantation - Progress and promise

Drugs of Today

Volumn 46, Issue 4, 2010, Pages 235-242

  Rangel, Érika B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD80; MONOCLONAL ANTIBODY CD86; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; EXPERIMENTAL TRANSPLANTATION; GRAFT REJECTION; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ACUTE DISEASE; ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION;

EID: 77954395493     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.4.1446426     Document Type: Review

References (41)

1. Cecka, J.M. Kidney transplantation in the United States. Clin Transpt 2008, 1-18.
2. Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., Cosimi, A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346(8): 580-90. (Pubitemid 34438820)
3. Vincenti, F., Schena, F.P., Paraskevas, S., Hauser, I.A., Walker, R.G., Grinyo, J. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008, 8(2): 307-16.
4. Pascual, J., Zamora, J., Galeano, C., Royuela, A., Quereda, C. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009, (1): CD005632.
5. Flechner, S.M., Kobashigawa, J., Klintmalm, G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008, 22(1): 1-15.
6. Gallagher, M., Jardine, M., Perkovic, V., Cass, A., McDonald, S., Petrie, J., Eris, J. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009, 87(12): 1877-83.
7. Flechner, S.M., Goldfarb, D., Solez, K., et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83(7): 883-92.
8. Fletcher, J.T., Nankivell, B.J., Alexander, S.I. Chronic allograft nephropathy. Pediatr Nephrol 2009, 24(8): 1465-71.
9. Nankivell, B.J., Borrows, R.J., Fung, C.L., O'Connell, P.J., Allen, R.D., Chapman, J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349(24): 2326-33.
10. Yabu, J.M., Vincenti, F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 2007, 27(4): 479-86. (Pubitemid 47002072)
11. Halloran, P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351(26): 2715-29.
12. Vincenti, F., Kirk, A.D. What's next in the pipeline. Am J Transplant 2008, 8(10): 1972-81.
13. Cruzado, J.M., Bestard, O., Grinyó, J.M. New immunosuppressive protocols with the advent of novel biological drugs. Transplantation 2009, 88(3 Suppl): S20-3.
14. Krummel, M.F., Allison, J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182(2): 459-65.
15. Sayegh, M.H., Turka, L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998, 338(25): 1813-21.
16. Vincenti, F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008, 121(2): 299-306.
17. Larsen, C.P., Pearson, T.C., Adams, A.B. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5(3): 443-53.
18. Greene, J.L., Leytze, G.M., Emswiler, J., Peach, R., Bajorath, J., Cosand, W., Linsley, P.S. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 1996, 271(43): 26762-71.
19. Linsley, P.S., Greene, J.L., Brady, W., Bajorath, J., Ledbetter, J.A., Peach, R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1(9): 793-801.
20. Latek, R., Fleener, C., Lamian, V. et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009, 87(6): 926-33.
21. Vierboom, M.P., Ossevoort, M., Sick, E.A., Haanstra, K., Jonker, M. Induction of allograft tolerance through costimulatory blockade: first selection of drugs in vitro. Transpl Immunol 2003, 11(2): 215-22.
22. Ossevoort, M.A., Ringers, J., Kuhn, E.M. et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999, 68(7): 1010-8.
23. Kirk, A.D., Tadaki, D.K., Celniker, A. et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001, 72(3): 377-84. (Pubitemid 32769620)
24. Montgomery, S.P., Xu, H., Tadaki, D.K. et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 2002, 74(10): 1365-9.
25. Emamaullee, J.A., Merani, S., Larsen, C.P., Shapiro, A.M. Belatacept and basiliximab diminish human antiporcine xenoreactivity and synergize to inhibit alloimmunity. Transplantation 2008, 85(1): 118-24.
26. Vincenti, F., Larsen, C., Durrbach, A. et al.; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353(8): 770-81.
27. Pondrom, S. The AJT report: News and issues that affect organ and tissue transplantation. Belatacept results promising.with some caveats. Am J Transplant 2009, 9(11): 2445-6.
28. Vincenti, F., Charpentier, B., Vanrenterghem, Y. et al. A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). Am J Transplant 2010, 10(3): 535-46.
29. Durrbach, A., Pestana, J.M., Pearson, T. et al. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study). Am J Transplant 2010, 10(3): 547-57.
30. Bremer, S., Vethe, N.T., Rootwelt, H. et al. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study. J Transl Med 2009, 7:64.
31. Ashman, N., Chapagain, A., Dobbie, H., Raftery, M.J., Sheaff, M.T., Yaqoob, M.M. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009, 9(2): 424-7.
32. Perez, V.L., Van Parijs, L., Biuckians, A., Zheng, X.X., Strom, T.B., Abbas, A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997, 6(4): 411-7. (Pubitemid 27208196)
33. Akalin, E., Chandraker, A., Russell, M.E., Turka, L.A., Hancock, W.W., Sayegh, M.H. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 1996, 62(12): 1942-5.
34. Sayegh, M.H., Akalin, E., Hancock, W.W., Russell, M.E., Carpenter, C.B., Linsley, P.S., Turka, L.A. CD28-B7 blockade after alloantigenlc challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995, 181(5): 1869-74.
35. Dekel, B., Böcher, W.O., Marcus, H., Yussim, A., Reisner, Y. Acute cellular rejection of human renal tissue by adoptive transfer of allogeneic human peripheral blood mononuclear cells into chimeric rats: sequential gene expression of cytokines, chemokines and cytolytic effector molecules, and their regulation by CTLA-4-Ig. Int Immunol 1999, 11(10): 1673-83.
36. Tang, Q., Henriksen, K.J., Boden, E.K. et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003 171(7): 3348-52.
37. Lohr, J., Knoechel, B., Abbas, A.K. Regulatory T cells in the periphery. Immunol Rev 2006, 212: 149-62.
38. Bluestone, J.A., Liu, W., Yabu, J.M. et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8(10): 2086-96.
39. Lakkis, F.G., Sayegh, M.H. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003, 14(9): 2402-10.
40. Wu, Z., Bensinger, S.J., Zhang, J. et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004, 10(1): 87-92.
41. Haidinger, M., Hecking, M., Memarsadeghi, M., Weichhart, T., Werzowa, J., Hört, W.H., Säemann, M.D. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept. Transpl Infect Dis 2009, 11(2): 171-4.